NRC Health Finance Lease, Right-of-Use Asset, Amortization
NRC Health (NRC) reported Finance Lease, Right-of-Use Asset, Amortization of $9.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-03-05
- NRC Health finance lease, right-of-use asset, amortization for the quarter ending 2020-03-31 was $61.00K, a 0.00% change year-over-year.
- NRC Health finance lease, right-of-use asset, amortization for the quarter ending 2019-12-31 was $63.00K.
- NRC Health finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $65.00K.
- NRC Health finance lease, right-of-use asset, amortization for the quarter ending 2019-06-30 was $63.00K.
- NRC Health finance lease, right-of-use asset, amortization for fiscal 2025 was $9.00K, a 64.00% decline from fiscal 2024.
- NRC Health finance lease, right-of-use asset, amortization for fiscal 2024 was $25.00K, a 91.94% decline from fiscal 2023.
- NRC Health finance lease, right-of-use asset, amortization for fiscal 2023 was $310.00K, a 32.90% decline from fiscal 2022.
- NRC Health finance lease, right-of-use asset, amortization for fiscal 2022 was $462.00K, a 5.52% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $9.00K 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $25.00K 10-K · filed 2026-03-05 | |||
| 2023-12-31 | $310.00K 10-K · filed 2026-03-05 | |||
| 2022-12-31 | $462.00K 10-K · filed 2025-03-17 | |||
| 2021-12-31 | $489.00K 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $355.00K 10-K · filed 2023-03-03 | |||
| 2020-03-31 | $61.00K 10-Q · filed 2020-05-08 | $124.00K derived: sum of 2 quarters · filed 2022-03-04 | $189.00K derived: sum of 3 quarters · filed 2022-03-04 | $252.00K derived: sum of 4 quarters · filed 2022-03-04 |
| 2019-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $128.00K derived: sum of 2 quarters · filed 2022-03-04 | $191.00K derived: sum of 3 quarters · filed 2022-03-04 | $252.00K 10-K · filed 2022-03-04 |
| 2019-09-30 | $65.00K 10-Q · filed 2019-11-08 | $128.00K derived: sum of 2 quarters · filed 2019-11-08 | $189.00K 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $63.00K 10-Q · filed 2019-08-08 | $124.00K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $61.00K 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |